Eosinophilia, myositis, and myasthenia gravis associated with a thymoma.
Hypereosinophilia has been associated with a wide variety of systemic disorders, including myositis. Myositis develops in a minority of patients with myasthenia gravis associated with a thymoma. We present a patient who developed a life-threatening myopathy in which testing demonstrated the concurrence of hypereosinophilia, myositis, and myasthenia gravis associated with thymoma. Thymoma-associated T-cell abnormalities may well have contributed to this rare association. This case underscores the need to reevaluate constantly the presumed cause of clinical complaints, as more than one cause may be present.
Avni
Irit
I
Internal Medicine D, Sheba Medical Center, Tel Hashomer, 52621, Israel.
Sharabi
Yehonatan
Y
Sadeh
Menachem
M
Buchman
Aron S
AS
D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001772:Blood Cell Count; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D004802:Eosinophilia / Q000150:complications* / Q000473:pathology; D005133:Eye Movements; D006801:Humans; D008297:Male; D018482:Muscle, Skeletal / Q000473:pathology; D009157:Myasthenia Gravis / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D009220:Myositis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D009431:Neural Conduction; D009460:Neurologic Examination; D010538:Peritonitis / Q000209:etiology; D011241:Prednisone / Q000627:therapeutic use; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D013945:Thymoma / Q000150:complications* / Q000473:pathology; D013953:Thymus Neoplasms / Q000150:complications* / Q000473:pathology
D000893:Anti-Inflammatory Agents; D002800:Cholinesterase Inhibitors; D011729:Pyridostigmine Bromide; D011241:Prednisone